Bristol-Myers Squibb and MESO SCALE DISCOVERY : Agreement to Develop Diagnostic Assays for Alzheimer's Disease

March 28, 2012  – Bristol-Myers Squibb Company (NYSE:BMY) and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

Under the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery® MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer's disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

"The collaboration with Meso Scale Discovery demonstrates Bristol-Myers Squibb's commitment to advancing the science of Alzheimer's disease research," said Jane Tiller, vice president, Global Clinical Research, Bristol-Myers Squibb. "These assays could provide the Alzheimer's disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer's disease."... Meso Scale Discovery's Press Release - Bristol-Myers Squibb's Press Releases -